Cognition Therapeutics Initiates NIA-Funded SNAP study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer’s Disease Press Release , June 5th, 2018
Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting Press Release, March 14th, 2018
Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum Press Release, January 4th, 2018
Cognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse Recovery Press Release, November 4th, 2017
Pharm company plans to start clinic trials of Alzheimer’s treatment by year-end Pittsburgh Business Times, September 9th, 2015
Cognition Therapeutics Completes Oversubscribed $12 Million Series B Financing Press Release, September 8th, 2015